Glucagonoma: A recent series of 7 cases;Le glucagonome: À propos d'une série récente de 7 cas

Bulletin du Cancer

Volumn 91, Issue 7-8, 2004, Pages 637-640

  Vauléon, Elodie ^a   Egreteau, Joëlle ^a   Boucher, Eveline ^a   Desfourneaux, Véronique ^b   Bretagne, Jean François ^c   Raoul, Jean Luc ^a  

^a CENTRE EUGÈNE MARQUIS   (France)

^b Dept de Chirurgie Viscerale ^*  (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Glucagonoma; Necrolytic migratory erythema; Somatostatin; Treatment

Indexed keywords

SOMATOSTATIN;

ADULT; AGED; ANAMNESIS; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE SEVERITY; ENDOCRINE TUMOR; FAMILY HISTORY; FEMALE; FOLLOW UP; GLUCAGONOMA; HEALTH STATUS; HISTOLOGY; HUMAN; HYPERGLUCAGONEMIA; JAUNDICE; LIVER METASTASIS; MALE; PROGNOSIS;

ADULT; AGED; ERYTHEMA; FEMALE; GLUCAGONOMA; HORMONES; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SOMATOSTATIN;

EID: 4344624319     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Vinik AI, Moattari AR. Treatment of endocrine tumor of the pancreas. Endocrinol Metab Clin North Am 1989 ; 18 : 483-518.
2. Mignon M, Cadiot G, Vallot T, Ruzniewski P. Diagnostic des tumeurs neuro-endocrines digestives. Paris : Doin Eds; 1996. Progrès en Hépatogastroentérologie.
3. Serup P, Jensen J, Andersen FG, Jorgensen MC, Elume N, Holst JJ, et al. Induction of insulin and islet amyloid polypeptide production in pancreatic islet glucagonoma cells by insulin promoter factor 1. Proc Natl Acad Sci USA 1996 ; 93 : 9015-20.
4. Yano T, Yamamoto N, Fujimori K, Inamori S, Hiyashi H, Mizumoto R. Glucagon-secreting pancreatic islet cell carcinoma, containing insulin and somatostatin, with hypoglycemic attack. Am J Gastroenterol 1982 ; 77 : 387-91.
5. Soga J, Yakuwa Y. Glucagonomas/diabetico-dermatogenic syndrome (DDS) : a statistical evaluation of 407 reported cases. J Hepatobiliary Pancreat Surg 1998 ; 5 : 312-9.
6. Chastain MA. The glucagonoma syndrome : a review of its features and discussions of new perspectives. Am J Med Sci 2001 ; 321 : 306-20.
7. Bouin M, d'Aoust L. Réponse clinique d'un glucagonome atypique à un traitement par analogue de la somatostatine. Gastroenterol Clin Biol 2002 ; 26 : 926-9.
8. Delcore R, Friesen SR. Gastrointestinal neuroendocrine tumors. J Am Coll Surg 1994 ; 178 : 187-211.
9. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine 1996 ; 75 : 53-63.
10. Calender A, Cadiot G, Mignon M, Gresze, Genem. Néoplasie endocrinienne multiple de type 1 : aspects génétiques et cliniques. Gastroenterol Clin Biol 2001 ; 25 : B38-B48.
11. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997 ; 38 : 853-8.
12. Forster GJ, Engelbach MJ, Brockmann JJ, Repert HJ, Buchholz HG, Macke HR, et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours : comparison of (86)Y-DOTATOC and (111)In-DTPA-octretide. Eur J Nucl Med 2001 ; 28 : 1743-50.
13. Buscombe J, Caplin ME, Hilson AJ. Long-term efficacy of high-activity 111In-pentreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 2003 ; 44 : 1-6.
14. Souquet JC, Sassolas G, Forichon J, Champetier P, Partensky C, Chayvialle JA. Clinical and hormonal effects of long-acting analogs in pancreatic endocrin tumors and in carcinoid syndrome. Cancer 1987 ; 59 : 1654-60.
15. Saltz L, Trochanowski B, Bucley M, Heffernan B, Niedzwiecki D, Tao Y, et al. Octreotide as an antineoplastic agent in the treatment of functionnal and nonfunctionnal neuroendocrine tumors. Cancer 1993 ; 72 : 244-8.
16. Faiss S, Pape UF, Bohmig M, Dorfett Y, Mansmann U, Golder W, et al. Prospective randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - The International Lanreotide Interferon Alfa Study Group. J Clin Oncol 2003 ; 15 : 2689-96.
17. Matthews BD, Smith TI, Ketcher KW, Holder WD, Heniford BT. Surgical experience with functionning pancreatic neuroendocrine tumors. Am Surg 2002 ; 68 : 660-5.
18. Chu QD, Al-kasspooles MF, Smith JL, Nava HR, Douglass HO, Driscoll D, et al. Is glucagonoma of the pancreas a curable disease ? Int J Pancreatol 2001 ; 29 : 155-62.
19. Sarmiento JM, Que FG, Grant CS, Thompson GB, Farnell MB, Nagorney DM. Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases : outcomes of an aggressive approach. Surgery 2002 ; 132 : 976-82.
20. Lepage C, Bouvier AM, Phelip JM, Hatem C, Coatmeur O, Vernet C, et al. Incidence et prise en charge des tumeurs endocrines malignes : étude de population en Côte d'Or et Saône-et-Loire de 1976 à 1999. Gastroenterol Clin Biol 2003 ; 27 : A 162.